No Data
No Data
Milestone Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare
Strong Buy Rating for Milestone Pharmaceuticals Amidst Promising CARDAMYST Prospects and Market Strategy
Express News | FDA Accepts Milestone Pharmaceuticals' New Drug Application For Cardamyst (Etripamil) Nasal Spray, To Manage Paroxysmal Supraventricular Tachycardia Prescription Drug User Fee Act Is 10 Months From The Acceptance Date Of May 26, 2024
Express News | Milestone Pharmaceuticals Inc: FDA Prescription Drug User Fee Act (Pdufa) Target Date Is 10 Months From Acceptance Date of May 26, 2024.
Express News | Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for Cardamyst™
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST
The FDA's acceptance of our NDA for CARDAMYST brings Milestone one step closer in our mission in providing a new, convenient and effective treatment option for patients with PSVT.
No Data